Although evidence suggests that amyloid deposits (or "plaques") in the brain are associated with an increased risk of cognitive decline, the impact of being "amyloid positive" on the likelihood and timing of progressing to Alzheimer's dementia on an individual basis remains unknown.
+Alzheimer's Reading Room
The beginning of secondary prevention trials in people with presymptomatic Alzheimer's provides an important research opportunity to evaluate the impact of learning one's amyloid status.
One such trial is the Anti-Amyloid treatment of Asymptomatic Alzheimer's disease (A4) trial being proposed by the Alzheimer's Disease Cooperative Study.
|Subscribe to the Alzheimer's Reading Room|
PET amyloid imaging and/or cerebrospinal fluid markers of beta amyloid accumulation will be used to select participants for the trial, which will test an experimental treatment in older adults who are cognitively normal and amyloid-positive for three years.
The goal is to test the hypothesis that decreasing "upstream" amyloid accumulation will slow "downstream" brain cell death and cognitive decline.
The video is informative and well worth watching. Should be shared in the Alzheimer's community.
- Test Your Memory for Alzheimer's (5 Best Tests)
- What is the Difference Between Alzheimer’s and Dementia
- Dementia and the Eight Types of Dementia
- Learning How to Communicate with Someone Suffering From Alzheimer's Disease
- 10 Things a Person Living with Dementia Would Tell You If They Could
- Alzheimer's, Urinary Incontinence, Urinary Tract Infections
- Rewiring My Brain and Stepping into Alzheimer's World
Original content +Bob DeMarco , the Alzheimer's Reading Room